Given the discussions above on Biogen's decision and neurofilament biomarkers, this comment jumped out at me in this article :
https://endpts.com/biogen-and-ionis-abandon-als-drug-after-disappointing-early-stage-trial/
That's pretty big news for PAA and MPL.
Frontotemporal degeneration stands out as a very adjacent indication to MND/ALS , and if MPL is proven efficacious against MND ( including +ve results in NfL's ) , odds on it would also prove efficacious against FTD - and neurofilament markers would qualify as a validated endpoint in clinical studies.
Ann: PharmAust receives Orphan Drug Designation for monepantel, page-43
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.5¢ |
Change
0.010(4.88%) |
Mkt cap ! $104.6M | |||
| Open | High | Low | Value | Volume |
| 20.5¢ | 21.5¢ | 20.5¢ | $244.1K | 1.163M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 71981 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 84173 | 3 |
View Market Depth
| Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
| PAA (ASX) Chart |